• Assure Holdings (IOM) has been approved to list its shares on the NASDAQ Capital Market
  • Trading will begin on September 29, 2021, under the ticker symbol IONM
  • The company believes the listing will benefit its liquidity and appeal for potential future acquisitions
  • Assure Holdings provides a turnkey suite of services that support intraoperative neuromonitoring activities during invasive surgeries
  • Assure Holdings (IOM) is unchanged trading at $9.30 per share

Assure Holdings (IOM) has been approved to list its shares on the NASDAQ Capital Market.

Trading will begin on September 29, 2021, under the ticker symbol IONM.

The company’s stock will continue trading on the OTCQB Venture Market until trading commences on the NASDAQ.

It will retain its listing on the TSXV.

John A. Farlinger, Assure’s Executive Chairman and CEO, stated,

“Our listing on NASDAQ represents a significant milestone for Assure. We believe that a NASDAQ listing increases Assure’s visibility in the industry. In addition, the listing is expected to provide increased liquidity to our investors, improve our access to capital and enhance the value of our common stock for future M&A transactions.”

Assure Holdings provides a turnkey suite of services that support intraoperative neuromonitoring activities during invasive surgeries.

Assure Holdings (IOM) is unchanged trading at $9.30 per share as of 11:35 am ET.

More From The Market Online

Calian scores $23 million Canadian Armed Forces contract

Calian Group Ltd. (TSX:CGY) has been awarded a $17 million contract by the Canadian Armed Forces’ Canadian Forces Health Services Group.

Unsung profits: Three microcap stocks with a strong case for value

A key factor behind picking winning microcap value stocks is identifying dislocations between company performance and market perception.

This life sciences company is gearing up to treat long COVID  

Revive Therapeutics (CSE:RVV), a Toronto-based company, has immense potential to capitalize on treating long COVID symptoms.

Theralase advances cancer research after private placement

Theralase Technologies (TSXV:TLT) closes a non-brokered private placement offering of 4.1 million shares for gross proceeds of C$750,200.